Incyte

FDA granted orphan drug designation to VGT-1849A, a selective ASO-based JAK2 inhibitor for treating polycythemia vera (PV). PV, a rare hematologic malignancy, affects 1 in 2000 individuals in the US and is caused by a JAK2 V617F mutation. VGT-1849A aims to reduce JAK2 activity, potentially offering targeted efficacy and improved safety over current JAK2 inhibitors.

Patients with chronic graft-versus-host disease (cGVHD) treated with belumosudil often received it after 3+ prior therapies, typically in combination. Median starting dose was 200 mg/day, with 30.4% receiving twice-daily dosing. Most patients initiated belumosudil 489 days post-diagnosis, often in later lines of therapy. Common prior regimens included ruxolitinib and calcineurin inhibitors. Belumosudil was prescribed alone or with corticosteroids for 45.9% of patients, and in combination for 54.1%. Median follow-up was 449 days, with 12.7% continuing initial therapy, 20.4% adding therapies, 27.1% switching, and 39.8% discontinuing, of which 24% were rechallenged.

DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.

Navtemadlin, a potent MDM2i, shows promise in treating myelofibrosis (MF) patients relapsed or refractory to JAKi therapy, with notable activity in bone marrow fibrosis reduction and driver mutation allele burden. The POIESIS trial (NCT06479135) aims to evaluate navtemadlin as an add-on to ruxolitinib in JAKi-naïve MF patients with suboptimal responses, seeking to improve SVR35 and TSS50 rates.

Tafasitamab-cxix (Monjuvi) demonstrated real-world effectiveness in US patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with progression-free survival (PFS) of 11.3 months and overall survival (OS) of 24.8 months. The overall response rate (ORR) was 73.5%, including 23.2% complete response (CR) and 50.3% partial response (PR). Factors increasing progression risk included later-line therapy, advanced disease stage, higher comorbidity index, and bulky disease. Increased mortality risk factors included later-line therapy, older age, higher ECOG performance status, and bulky disease. The study highlights tafasitamab's clinical benefit, particularly when used in second-line therapy.

Real-world data on tafasitamab-cxix (Monjuvi) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed PFS of 11.3 months and OS of 24.8 months, with an ORR of 73.5%. Factors like later-line use, advanced disease stage, higher comorbidity scores, and bulky disease increased progression risk. Tafasitamab's effectiveness was greatest in second-line therapy, with CR rates of 23.2% and PR rates of 50.3%.

Nifty 50's volatility since late September has ranked it among the worst-performing global markets, with -5.6% returns in the last 10 weeks and 13.7% year-to-date. Factors like geopolitical issues, elevated valuations, and weak corporate earnings contributed to this performance. Despite this, 27 stocks have outperformed, delivering an average return of 60.8%.

Tafasitamab showed promising real-world efficacy in relapsed/refractory DLBCL, with PFS of 11.3 months, OS of 24.8 months, and ORR of 73.5% in US patients. Factors like later-line therapy, advanced disease stage, and higher comorbidity scores increased progression risk.

The Oncology Market is critical in global healthcare, driven by cancer prevalence, technological advancements, and strategic collaborations. Key players like Daiichi Sankyo, Bayer AG, and others innovate in diagnostics, treatments, and precision medicine. Market growth is fueled by R&D investments, sustainability focus, and consumer awareness. Challenges include regulatory constraints and talent shortages. Technological integrations like AI and IoT enhance patient care and operational efficiency.

The MANIFEST-2 trial (NCT04603495) showed pelabresib (CPI-0610; Novartis) plus ruxolitinib (Jakafi; Incyte Corp) improved spleen volume, total symptom score (TSS), anemia, and bone marrow fibrosis (BMF) in JAK inhibitor-naïve myelofibrosis (MF) patients compared to ruxolitinib and placebo. At week 24, 65.9% achieved SVR35, and at week 48, 56.5% achieved SVR35 with pelabresib and ruxolitinib, versus 37.5% with placebo and ruxolitinib. The data will be presented at the 66th ASH Annual Meeting and Exposition on December 8, 2024.